Skip to main content

KYMRIAH (Novartis Pharmaceuticals Australia Pty Ltd)

Product name
Date registered
Evaluation commenced
Decision date
Approval time
45 working days (255)
Active ingredients
T Cells - Tisagenlecleucel, cryopreserved - T - Kymriah
Registration type
Class 4 biological

KYMRIAH is a genetically modified autologous immunocellular therapy indicated for the treatment of paediatric and young adult patients up to 25 years of age with B-cell precursor acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant, or in second or later relapse.

Help us improve the Therapeutic Goods Administration site